Treatment of autoimmune liver disease: current and future therapeutic options

Palak J Trivedi, Gideon M Hirschfield

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)


Autoimmune liver disease spans three predominant processes, from the interface hepatitis of autoimmune hepatitis to the lymphocytic cholangitis of primary biliary cirrhosis, and finally the obstructive fibrosing sclerotic cholangiopathy of primary sclerosing cholangitis. Although all autoimmune in origin, they differ in their epidemiology, presentation and response to immunosuppressive therapy and bile acid based treatments. With an ongoing better appreciation of disease aetiology and pathogenesis, treatment is set ultimately to become more rational. We provide an overview of current and future therapies for patients with autoimmune liver disease, with an emphasis placed on some of the evidence that drives current practice.

Original languageEnglish
Pages (from-to)119-41
Number of pages23
JournalTherapeutic advances in chronic disease
Issue number3
Publication statusPublished - May 2013


Dive into the research topics of 'Treatment of autoimmune liver disease: current and future therapeutic options'. Together they form a unique fingerprint.

Cite this